«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

21卷

期数:

2015年06期

页码:

507-509

栏目:

临床医学

出版日期:

2015-11-20

文章信息/Info

Title:

Diagnostic value of FibroTest combined with four serum liver fibrosis biomarkers for liver fibrosis in patients with chronic hepatitis B

文章编号:

1006-8147（2015）06-0507-03

作者:

申晓敏¹ ; 王春妍² ; 程晓静³

(天津市第二人民医院检验科,天津 300192)

Author(s):

?SHEN Xiao-min¹;WANG Chun-yan²;CHENG Xiao-jing³

( Department of Clinical Laboratories,The Second People’s Hospital of Tianjin, Tianjin 300192)

关键词:

肝硬化; 乙型肝炎病毒; FibroTest ; 肝纤维化4项指标

Keywords:

liver cirrhosis;  hepatitis B virus;  FibroTest; four serum liver fibrosis biomarkers

分类号:

R512.6+2

DOI:

-

文献标志码:

A

摘要:

?目的： 探讨采用FibroTest（FT）与肝纤维化4项指标（肝纤4项）两种检测方法判断慢性乙型肝炎肝纤维化程度的意义。方法： 留取90 例慢性乙型肝炎患者血清，受试者均于同期进行肝穿刺活检，依据活检分期进行分组，分别检测α2巨球蛋白、 结合珠蛋白、 γ- 谷氨酰转肽酶、 总胆红素和载脂蛋白 AⅠ5个指标， 根据性别及年龄计算FT值，同时检测血清肝纤4项透明质酸、 层粘蛋白、 Ⅲ型前胶原、 Ⅳ型胶原，评价FT值和肝纤4项在慢性乙型肝炎肝纤维化程度判断中的价值。结果： 肝脏病理纤维化分期为S0期5例（5.55%）、S1期49例（54.44%）、S2 24例(26.67%)、S3 7例（7.78%）、S4 5例（5.56%）。90例患者S 0、S 1、S 2、S 3、S 4 期的各个检测值两两比较，差异具有统计学意义， P ＜0．001。各检测值与肝脏病理分期呈正相关，P ＜0.01。结论： FibroTest联合肝纤4项在慢性乙型肝炎肝纤维化程度判断中有一定价值。

Abstract:

Objective ： To investigate the diagnostic value of FibroTest combined with 4 serum liver fibrosis biomarkers for liver fibrosis in patients with chronic hepatitis B (CHB)．Methods ： Serum samples were collected from 90 CHB patients who underwent liver biopsy. Serum samples were tested for five indicators including α2- macroglobulin (α2M)，haptoglobin (HAP)，γ- glutamyl peptidase (GGT)，total bilirubin (BIL) and apolipoprotein aⅠ(Apo AⅠ) and then the FT values as well as the age and sex of patients were calculated．Four serum liver fibrosis biomarkers included HA,LN, PⅢ，Ⅳ- C were tested. The diagnostic values of FibroTest and Four serum liver fibrosis biomarkers for liver fibrosis in CHB patients were evaluated. Results： We found 5 cases （5.55%）in the S 0 stage (the pathological stage of liver fibrosis)，49 cases （54.44%）in the S 1stage， 24 cases (26.67%) in the S 2 stage，7 cases （7.78%）in the S 3 stage and 5 cases （5.56%）in the S 4 stage．The values were significantly different between any two of the five Stages(S 0 - S 4 ) (all P ＜0.001)． A positive correlation was found between the values and liver pathological stage( P＜0.01)．Conclusion The combination of FibroTest and Four serum liver fibrosis biomarkers can evaluate liver fibrosis in CHB patients .

参考文献/References:

?

[1]	郭争捷，常建东，王卫民，等.声触诊组织量化技术诊断肝纤维化［J］．中国介入影像与治疗学，2012，9(10):718
[2]	中华医学会肝病学分会、 感染病学分会． 慢性乙型肝炎防治指南(2010 年版 )［ J］.临床肝胆病杂志， 2011，27(1):Ⅰ
[3]	叶小萍，冉海．声触诊组织量化技术无创评估肝纤维化的研究进展［J］． 中国介入影像与治疗学， 2012，9(4): 311
[4]	许为民. TBA 以及肝纤四项在肝病中的检测意义[J]．齐齐哈尔医学院学报，2011 ，32（4）：554
[5]	贾晓娟，许泽清，南永刚,等．肝纤四项在乙肝携带的肝癌患者血清中的表达情况[J]．中外医学研究，2013，11（9）：41
[6]	Myers ＲP，Tainturier M H，ＲATZIU V，et al． Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B［J］．J Hepatol，2003，39(2):222
[7]	Munteanu M． Noninvasive biomarkers FibroTest actitest for replacing invasive liver biopsy: the need for change and action［J］． J Gastrointestin Liver Dis，2007，16(2):173
[8]	Poynard T，de Ledinghen V，Zarski J P，et al．Ｒelative performances of FibroTest，fibroscan，and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard［J］． Hepatology,2012，56(3):541
[9]	程晓静，陆 伟，侯 伟, 等．FibroTest 联合 FibroScan 对慢性乙型肝炎肝纤维化的诊断价值[J]．临床肝胆病杂志，2014，30（5 ）：424
[10]	张 砚，王春妍， 程晓静,等.FibroTest 在慢性乙型肝炎肝纤维化程度判断中的应用[J].山东医药，2014，54（19）：12

相似文献/References:

[1]程婷婷,王凤梅,朱争艳,等.HBV慢性感染者肝脏组织中CD4+T、CD8+T和FoxP3+Tregs细胞的表达水平[J].天津医科大学学报,2016,22(02):129.
　CHENG Ting-ting,WANG Feng-mei,ZHU Zheng-yan,et al.Level of CD4+T、CD8+T and FoxP3+Tregs in the liver tissues of patients with chronic HBV infection[J].Journal of Tianjin Medical University,2016,22(06):129.
[2]杨 柳,王绕绕,尹明丽,等.自体特异性免疫效应淋巴细胞抑制转HBV基因小鼠HBV复制的研究[J].天津医科大学学报,2017,23(01):11.
　YANG Liu,WANG Rao-rao,YIN Ming-li,et al.Study on effect of autologous specific immune effective cells on inhibiting HBV replication in HBV transgenic mice[J].Journal of Tianjin Medical University,2017,23(06):11.
[3]周冷潇,韩 涛.慢性乙型病毒性肝炎肝硬化发生肝细胞癌的危险因素分析[J].天津医科大学学报,2017,23(03):214.
　ZHOU Leng-xiao,HAN Tao.Risk factors of hepatocellular carcinoma in patients with hepatitis B virus-related liver cirrhosis[J].Journal of Tianjin Medical University,2017,23(06):214.
[4]周冷潇,韩 涛,刘 芳.无创肝纤维化指标结合甲胎蛋白对乙型肝炎相关肝细胞癌的评估[J].天津医科大学学报,2017,23(05):415.
　ZHOU Leng-xiao,HAN Tao,LIU Fang.Assessment of non-invasive fibrosis indexes with alpha-fetoprotein?for? hepatitis B virus-related hepatocellular carcinoma[J].Journal of Tianjin Medical University,2017,23(06):415.
[5]姜海波,王俊梅,刘贯华.ERCP治疗胆总管结石合并肝硬化的效果分析[J].天津医科大学学报,2018,24(02):162.
　JIANG Hai-bo,WANG Jun-mei,LIU Guan-hua.Effect of ERCP in the treatment of common bile duct stones complicated with cirrhosis[J].Journal of Tianjin Medical University,2018,24(06):162.
[6]张丽梅,贾莉莉 综 述,喻文立 审 校.外泌体在病毒性肝炎、肝硬化和肝癌中的作用研究进展[J].天津医科大学学报,2019,25(03):305.
[7]谢永丽,汤华.YTHDF1对HBV蛋白表达和HBsAg和HBeAg抗原分泌的作用[J].天津医科大学学报,2021,27(05):461.
　XIE Yong-li,TANG Hua.Role of YTHDF1 on HBV protein expression and secretion of HBsAg and HBeAg antigens[J].Journal of Tianjin Medical University,2021,27(06):461.
[8]张荣芳,钱磊,常明杰,等.血清HBV RNA在慢性乙型肝炎抗病毒治疗过程中的动态变化及其临床意义[J].天津医科大学学报,2021,27(05):520.
　ZHANG Rong-fang,QIAN Lei,CHANG Ming-jie,et al.Dynamic changes and clinical significance of serum HBV RNA in patients with chronic hepatitis B during antiviral therapy[J].Journal of Tianjin Medical University,2021,27(06):520.
[9]胡善雷,李广明,任 娜,等.GP73在HBV相关性肝病中的水平及意义[J].天津医科大学学报,2019,25(06):615.
　HU Shan-lei,LI Guang-ming,REN Na,et al.The level and significance of GP73 in HBV related liver diseases[J].Journal of Tianjin Medical University,2019,25(06):615.

备注/Memo

备注/Memo:

作者简介 申晓敏（1979-），女，主管检验技师，硕士，研究方向：生化检验；E-mail：shenxiaomin420@163.com。

常用功能

更新日期/Last Update: 2015-11-27